KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $309.3 million.

  • Ionis Pharmaceuticals' Total Current Liabilities rose 196.64% to $903.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.5 million, marking a year-over-year increase of 196.64%. This contributed to the annual value of $309.3 million for FY2024, which is 30.97% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Total Current Liabilities of $309.3 million as of FY2024, which was down 30.97% from $448.1 million recorded in FY2023.
  • In the past 5 years, Ionis Pharmaceuticals' Total Current Liabilities registered a high of $598.9 million during FY2020, and its lowest value of $240.6 million during FY2021.
  • For the 3-year period, Ionis Pharmaceuticals' Total Current Liabilities averaged around $356.3 million, with its median value being $311.6 million (2022).
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Total Current Liabilities soared by 119.37% in 2020, and later crashed by 59.83% in 2021.
  • Ionis Pharmaceuticals' Total Current Liabilities (Yearly) stood at $598.9 million in 2020, then plummeted by 59.83% to $240.6 million in 2021, then grew by 29.52% to $311.6 million in 2022, then soared by 43.82% to $448.1 million in 2023, then tumbled by 30.97% to $309.3 million in 2024.